Search

Your search keyword '"Osteoporosis -- Drug therapy"' showing total 2,267 results
Start Over Descriptor "Osteoporosis -- Drug therapy"
2,267 results on '"Osteoporosis -- Drug therapy"'

2. CSIR - Central Drug Research Institute Researcher Advances Knowledge in Nanoemulsions (Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry)

Subjects
Women -- Health aspects, Osteoporosis -- Drug therapy, Postmenopausal women -- Drug therapy, Mass spectrometry -- Reports, Liquid chromatography -- Reports, Health, Women's issues/gender studies
Abstract

2024 MAY 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on nanoemulsions are presented in a new report. According to news originating [...]

Published
2024

3. Findings from Qingdao Municipal Hospital Has Provided New Data on Osteoporosis (Analyzing the Factors Associated With Efficacy Among Teriparatide Treatment In Postmenopausal Women With Osteoporosis)

Subjects
Women -- Health aspects, Osteoporosis -- Drug therapy, Postmenopausal women -- Drug therapy, Health, Women's issues/gender studies
Abstract

2024 MAR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Musculoskeletal Diseases and Conditions - Osteoporosis. According to news [...]

Published
2024

4. Osteoporosis treatment: Medications can help

Subjects
Osteoporosis -- Drug therapy, Phosphonates, Health
Abstract

If you're undergoing osteoporosis treatment, you're taking a step in the right direction for your bone health. But perhaps you have questions about your therapy. Is the medicine you're taking [...]

Published
2024

6. College of Medicine Researchers Update Understanding of Osteoporosis [Prevalence of Low Bone Mass and Osteoporosis in Ireland: the Dual-Energy X-Ray Absorptiometry (DXA) Health Informatics Prediction (HIP) Project]

Subjects
Women -- Health aspects, Osteoporosis -- Drug therapy, Medical informatics, Epidemiology, Health, Women's issues/gender studies, World Health Organization
Abstract

2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on osteoporosis. According to news reporting out of the College [...]

Published
2023

7. Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases

Subjects
Women -- Health aspects, Denosumab -- Methods -- Analysis, Osteoporosis -- Drug therapy, Military leaders -- Methods -- Analysis, Medical records -- Analysis -- Methods, Databases -- Methods -- Analysis, Epidemiology -- Methods -- Analysis, Electronic records -- Methods -- Analysis, CD-ROM catalog, Database, CD-ROM database, Health, Women's issues/gender studies
Abstract

2023 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

Published
2023

8. Jamia Hamdard Researchers Report Recent Findings in Osteoporosis (Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement)

Subjects
Osteoporosis -- Drug therapy, Drugs -- Vehicles, Nanoparticles -- Usage -- Health aspects -- Chemical properties, Risedronate -- Dosage and administration, Pharmaceutical research, Drug delivery systems -- Research, Bioavailability -- Research, Health
Abstract

2023 OCT 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on osteoporosis are discussed in a new report. According to [...]

Published
2023

10. Researchers at Queensland University of Technology Report New Data on Osteoporosis (Advances In Mechanobiological Pharmacokinetic-pharmacodynamic Models of Osteoporosis Treatment - Pathways To Optimise and Exploit Existing Therapies)

Subjects
Medical research -- Models -- Reports, Medicine, Experimental -- Models -- Reports, Denosumab -- Models -- Reports, Osteoporosis -- Drug therapy, Immunotherapy -- Models -- Reports, Health
Abstract

2024 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on Musculoskeletal Diseases and Conditions - Osteoporosis have been published. According to [...]

Published
2024

11. Data on Osteoporosis Detailed by Researchers at Department of Pharmacy (Gene Detection of Vdr Bsmi Locus and Its Approteins, Genes and Growthplication In Rational Drug Use In Patients With Osteoporosis)

Subjects
Osteoporosis -- Drug therapy, Genetic research, Genes, Genetic polymorphisms, Pharmacy, Health
Abstract

2024 JUL 26 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Musculoskeletal Diseases and Conditions - Osteoporosis have been presented. According [...]

Published
2024

13. Osteoporosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer Inc., Eli Lilly and Company, F. Hoffmann La Roche, Merck & Co

Subjects
Pfizer Inc. -- Product development, Teva Pharmaceutical Industries Ltd. -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Denosumab -- Reports, Osteoporosis -- Drug therapy, Clinical trials -- Reports, Business, Business, international, Prolia (Medication) -- Product development -- Reports
Abstract

M2 PRESSWIRE-April 2, 2024-: Osteoporosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer Inc., Eli Lilly and Company, F. Hoffmann La [...]

Published
2024

15. New Osteoporosis Study Findings Have Been Reported from University of Melbourne [Safer medicines To reduce falls and refractures for OsteoPorosis (#STOP): a study protocol for a randomised controlled trial of medical specialist-initiated ...]

Subjects
Falls (Accidents) -- Risk factors -- Demographic aspects -- Prevention, Osteoporosis -- Drug therapy, Aged patients -- Drug therapy -- Safety and security measures, Hypnotics -- Dosage and administration -- Complications and side effects, Fractures -- Risk factors -- Demographic aspects -- Prevention, Parasympatholytic agents -- Dosage and administration -- Complications and side effects, Sedatives -- Dosage and administration -- Complications and side effects, Health
Abstract

2023 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on osteoporosis is now available. According to news reporting [...]

Published
2023

16. Findings from Huazhong University of Science and Technology Broaden Understanding of Osteoporosis (Efficacy for Bone Deterioration in Mice with Osteoporosis and Pharmaceutical Properties of a Novel Compound Calcium Carbonate Granule)

Subjects
Osteoporosis -- Drug therapy, Dietary supplements -- Research, Pharmaceutical research, Calcium carbonate -- Health aspects, Health
Abstract

2023 JUL 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on osteoporosis. According to news reporting originating from [...]

Published
2023

17. CSIR - Central Drug Research Institute Researcher Advances Knowledge in Nanoemulsions (Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry)

Subjects
Women -- Health aspects, Osteoporosis -- Drug therapy, Postmenopausal women -- Drug therapy, Mass spectrometry -- Reports -- Laws, regulations and rules, Liquid chromatography -- Reports -- Laws, regulations and rules, Government regulation, Health care industry, Law
Abstract

2024 MAY 12 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Law Weekly -- Fresh data on nanoemulsions are presented in a new report. According to news [...]

Published
2024

18. Xi'an Chest Hospital Reports Findings in Osteoporosis (Network pharmacology analysis and experimental validation to explore the mechanism of kaempferol in the treatment of osteoporosis)

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Osteoporosis -- Drug therapy, Pharmacology -- Reports, Computers, News, opinion and commentary
Abstract

2024 APR 10 (VerticalNews) -- By a News Reporter-Staff News Editor at Computer Weekly News -- New research on Musculoskeletal Diseases and Conditions - Osteoporosis is the subject of a [...]

Published
2024

20. NEW DRUG SHOWS POTENTIAL TO AID ASTRONAUTS DURING FUTURE MISSIONS TO THE MOON AND MARS: BP-NELL-PEG has shown promising results of combatting microgravity bone loss in mice. However, it's yet to be tested in humans

Author

Kuthunur, Sharmlla

Subjects
Moon -- Discovery and exploration, Osteoporosis -- Drug therapy, Astronomy
Abstract

A cross the world, one person fractures a bone every three seconds due to a disease called osteoporosis, a common condition that weakens the bones of at least 10 million [...]

Published
2023

21. FDA Roundup: March 5, 2024

Subjects
United States. Food and Drug Administration, Denosumab, Osteoporosis -- Drug therapy, Drug approval, Business, News, opinion and commentary, Prolia (Medication), Xgeva (Medication)
Abstract

SILVER SPRING, Md., March 5, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced [...]

Published
2024

22. Sandoz receives Health Canada approval for Jubbonti(r), first & only denosumab biosimilar for treatment of osteoporosis

Subjects
Denosumab, Osteoporosis -- Drug therapy, Company business planning, General interest, News, opinion and commentary
Abstract

BOUCHERVILLE: Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti(r). Jubbonti(r) is Sandoz Canada's seventh biosimilar, demonstrating the company's ongoing commitment to grow its [...]

Published
2024

23. Sandoz receives Health Canada approval for Jubbonti(R), first and only denosumab biosimilar for treatment of osteoporosis

Subjects
Sandoz AG, Denosumab, Osteoporosis -- Drug therapy, Clinical trials, Pharmaceutical industry, Banking, finance and accounting industries, Business
Abstract

Biosimilar Jubbonti[sup.(R)] approved for all indications of Prolia* reference medicine. Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass. Health [...]

Published
2024

24. The osteoporosis drug market is expected to grow at a compound annual growth rate (CAGR) of 3.5% between 2023 and 2033, according to persistence market research

Subjects
Osteoporosis -- Drug therapy, Drugs -- Market research -- Market size, Marketing research -- Forecasts and trends, Monoclonal antibodies -- Growth, Pharmaceutical industry -- Market research -- Forecasts and trends -- Market size, Company growth, Marketing research, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

New York: The osteoporosis drug market is a rapidly growing sector in the pharmaceutical industry, driven by the aging population and the increasing prevalence of osteoporosis. The market is expected [...]

Published
2024

26. Hormone Preparations Tied to Increased Bone Mineral Density in Postmenopausal Women

Subjects
Osteoporosis -- Drug therapy, Postmenopausal women -- Drug therapy, Bones -- Density, Estrogen -- Reports, Oral contraceptives -- Reports, Health
Abstract

HealthDay News — Hormone preparations increase lumbar spine bone mineral density (BMD) in postmenopausal women, according to a study published online May 2 in Menopause. Yiran Wang, MD, and Chao [...]

Published
2023

27. Research from MacKay Memorial Hospital in the Area of Osteoporosis Published (Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview)

Subjects
Women -- Health aspects, Denosumab -- Reports, Osteoporosis -- Drug therapy, Corticosteroids -- Reports, Adrenocortical hormones -- Reports, Hormones -- Reports, Health, Women's issues/gender studies
Abstract

2023 APR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on osteoporosis is now available. According to news originating from Taipei, [...]

Published
2023

29. Data on Liposomes Reported by Researchers at Sichuan University (Bone-targeted Delivery of Senolytics To Eliminate Senescent Cells Increases Bone Formation In Senile Osteoporosis)

Subjects
Quercetin -- Usage -- Health aspects, Osteoporosis -- Drug therapy, Drugs -- Vehicles, Cell cycle -- Research, Pharmaceutical research, Drug delivery systems -- Research, Health
Abstract

2023 APR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Biotechnology - Liposomes is the subject of a report. [...]

Published
2023

30. New Findings from Guangdong Medical University in the Area of Osteoporosis Reported (Chiral Selenium Nanotherapeutics Regulates Selenoproteins To Attenuate Glucocorticoid-induced Osteoporosis)

Subjects
Corticosteroids -- Complications and side effects, Osteoporosis -- Drug therapy, Nanomedicine -- Research, Selenium -- Health aspects -- Usage, Nanoparticles -- Usage -- Health aspects, Selenoproteins -- Health aspects, Pharmaceutical research, Health
Abstract

2023 MAR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Musculoskeletal Diseases and Conditions - Osteoporosis have been [...]

Published
2023

32. Research Results from Intas Pharmaceuticals Ltd. Update Knowledge of Osteoporosis [Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis]

Subjects
Liposomes -- Usage -- Health aspects, Osteoporosis -- Drug therapy, Drugs -- Vehicles, Nanotechnology -- Usage -- Health aspects, Drug delivery systems -- Materials -- Technology application, Technology application, Health
Abstract

2023 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on osteoporosis have been published. According to news reporting [...]

Published
2023

33. Denosumab Biosimilar for Osteoporosis, Other Conditions Under FDA Review

Author

Ernst, Diana

Subjects
United States. Food and Drug Administration, Sandoz Inc., Denosumab, Osteoporosis -- Drug therapy, Pharmaceutical industry, Health
Abstract

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for a proposed biosimilar to denosumab. Denosumab is a RANK ligand inhibitor that is approved under the [...]

Published
2023

34. ACP Recommends Bisphosphonates for Initial Treatment of Osteoporosis

Author

Della Volpe, Kristin

Subjects
Osteoporosis -- Drug therapy, Denosumab -- Health aspects, Postmenopausal women -- Drug therapy, Patient compliance -- Health aspects, Health, American College of Physicians
Abstract

American College of Physicians (ACP) recommends clinicians use bisphosphonates (alendronate, ibandronate, risedronate, zoledronate) for initial pharmacologic treatment to reduce the risk for fractures in postmenopausal women and men diagnosed with [...]

Published
2023
Full Text
View/download PDF

35. ACP Updates Living Guideline on Pharmacologic Treatment of Osteoporosis

Subjects
Osteoporosis -- Drug therapy, Denosumab, Postmenopausal women -- Drug therapy, Practice guidelines (Medicine), Health, American College of Physicians
Abstract

HealthDay News — In a living clinical guideline issued by the American College of Physicians (ACP) and published online January 3 in the Annals of Internal Medicine, updated recommendations are [...]

Published
2023

36. Investigators from Indiana University School of Medicine Zero in on Alzheimer Disease (From the Mind To the Spine: the Intersecting World of Alzheimer's and Osteoporosis)

Subjects
Medical research, Medicine, Experimental, Osteoporosis -- Drug therapy, Alzheimer's disease -- Drug therapy, Health, Indiana University School of Medicine
Abstract

2024 MAR 15 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Neurodegenerative Diseases and Conditions - Alzheimer Disease have been [...]

Published
2024

37. FDA Approves Sandoz Biosimilars for Two Blockbuster Amgen Bone Drugs

Author

Vinluan, Frank

Subjects
Denosumab, Osteoporosis -- Drug therapy, Multiple myeloma -- Drug therapy, Drug approval, Prolia (Medication), Xgeva (Medication)
Abstract

https://medcitynews.com/2024/03/fda-approves-sandoz-biosimilars-for-two-blockbuster-amgen-bone-drugs/ Sandoz drugs Jubbonti and Xgeva are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to [...]

Published
2024

38. Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Subjects
Osteoporosis -- Drug therapy, Clinical trials, Banking, finance and accounting industries, Business
Abstract

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ('Entera' or the 'Company') a leader in the development of orally delivered peptides and therapeutic proteins, reported today [...]

Published
2023

39. Global Postmenopausal Osteoporosis Treatment Market is Expected to Reach US$ 15,171.90 million by 2034 | Future Market Insights, Inc. Projection

Subjects
Osteoporosis -- Drug therapy, Postmenopausal women -- Drug therapy, Conjugated estrogens -- Forecasts and trends, Industrial research -- Forecasts and trends, Research and development, Market trend/market analysis, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - The postmenopausal osteoporosis treatment market is estimated to be worth US$ 9863.6 million in 2024 and is projected to be valued at US$ 15,171.90 million in 2034. Between [...]

Published
2023

40. Global Postmenopausal Osteoporosis Treatment Market is Expected to Reach US$ 15,171.90 million by 2034 | Future Market Insights, Inc. Projection

Subjects
Osteoporosis -- Drug therapy, Postmenopausal women -- Drug therapy, Conjugated estrogens -- Forecasts and trends, Industrial research -- Forecasts and trends, Research and development, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

NEWARK, Del, Nov. 24, 2023 (GLOBE NEWSWIRE) -- The https://www.globenewswire.com/Tracker?data=fmIKj4N4TA-0N9Vadf6PY9lsKzwxxoKNNcnMUfP2mgZ8jisSPPf3rO2OdrfwueFoPZTeuKRyocbkohPHQIYuxGy6nm9-7Ighpprxu3IaIWuDZGfGffnr2kvSTrYveUqxZgUkCDG0fDzUph3fP-UQ9Jhs4SEgP3y7NIJ_VkHC9YUPlESqFZlIKPNvn_QaEgu7aAEzA0E7VbnEaX4Fj7GpIQ== is estimated to be worth US$ 9863.6 million in 2024 and is projected to be valued at US$ 15,171.90 million [...]

Published
2023

44. Entera Bio Reported Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Subjects
United States. Food and Drug Administration -- Planning, Osteoporosis -- Drug therapy, Drug approval, Peptides, Company business planning, General interest, News, opinion and commentary
Abstract

JERUSALEM: Entera Bio Ltd. (NASDAQ: ENTX), (Entera or the Company) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone [...]

Published
2023

45. Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Subjects
United States. Food and Drug Administration -- Planning, Osteoporosis -- Drug therapy, Drug approval, Peptides, Company business planning, Banking, finance and accounting industries, Business
Abstract

JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ('Entera' or the 'Company') a leader in the development of orally delivered peptides and therapeutic proteins, reports today [...]

Published
2023

48. FDA: Prolia Use in Dialysis Patients May Cause Severe Hypocalcemia

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Osteoporosis -- Drug therapy, Denosumab, Hypocalcemia -- Drug therapy, Drug approval, Kidney diseases -- Drug therapy, Health, Prolia (Medication)
Abstract

Patients with advanced kidney disease on dialysis who are treated with Prolia (denosumab) may be at risk of severe hypocalcemia with serious outcomes (eg, hospitalization and death), according to a [...]

Published
2022

49. Patients on Low-Dose Glucocorticoids Should Receive Anti-Osteoporotic Therapy

Author

Duffy, Steve

Subjects
Corticosteroids -- Dosage and administration, Osteoporosis -- Drug therapy, Rheumatoid factor -- Reports, Health
Abstract

Patients with inflammatory rheumatic musculoskeletal diseases (iRMDs) receiving low-dose glucocorticoids should also receive preventive anti-osteoporotic therapy, according to study results presented at ACR Convergence 2022, held from November 10 to [...]

Published
2022

50. ACR Updating Guideline for Glucocorticoid-Induced Osteoporosis

Subjects
Corticosteroids, Osteoporosis -- Drug therapy, Denosumab, Practice guidelines (Medicine), Health, American College of Rheumatology
Abstract

HealthDay News — In a summary of an updated clinical practice guideline issued by the American College of Rheumatology, recommendations are presented for the pharmacologic treatment of glucocorticoid-induced osteoporosis, with [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results